The lipoprotein metabolism regulator, APOC2, was found elevated in advanced stages of cancer for the first time, while it was previously described as a potential biomarker of CRC development.14 On the contrary, IGHG2 plasma levels were increased in CRC early stages and in patients with cancer-associated inflammation. This evidence concerns the gene APOC2 and colorectal carcinoma.